Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Elucidating the mechanism of action of protective monoclonal antibodies against Ebolavirus

FY 2013-14

Summary
Ebolavirus (EBOV) is one of the most aggressive pathogens known, and infections are characterized by a short incubation time as well as an onset of general symptoms, before rapidly progressing towards hemorrhage, shock and multi-system failure resulting in death in up to 90% of human cases. This virus has drawn considerable concern due to sporadic but devastating human outbreaks in sub-Saharan Africa, its suitability as a bio-weapon, and a prior instance of accidental introduction of EBOV to the USA from infected nonhuman primates (NHPs). Recent imported infections of the related Marburgvirus (MARV) to the Netherlands and the USA from tourists returning from travel in endemic areas have added to these concerns. The emergence of a new EBOV strain during the November 2007 outbreak in Uganda suggests that the virus is evolving. There are currently no prophylactic or therapeutic protocols approved for human use and current treatment consists only of palliative care. Previously, our research group has shown the importance of the humoral immune response in the context of host survival from EBOV infection. With this in mind, we developed a cocktail composed of three monoclonal antibodies (ZMAb) that when combined with adenovirus-vectored interferon as an adjuvant, is currently able to protect three of four cynomolgus macaques and four of four rhesus macaques when administered starting three days after EBOV infection. This is a significant achievement given that the current experimental options available have not been shown to be protective in NHPs if treatment is initiated past one hour after exposure to EBOV. Present research involves optimizing ZMAb, such that protection can still be achieved when administered later in the course of EBOV disease, or at lower antibody doses. However, the ability to further improve this treatment is hampered by the fact that the mechanism of action of these monoclonal antibodies is not yet known, although previous studies have indicated that antibody-mediated protection is not dependent on virus neutralization. The goal of this project is to elucidate this mechanism. EBOV sGP, a secreted form of the viral surface glycoprotein, is known to subvert the humoral response of the infected host such that potentially protective antibodies generated in response to the infection will cross-react with and be removed by sGP. We hypothesize that exogenous ZMAb acts by reducing sGP levels during infection and preventing the subversion of the humoral immune response, thereby improving the odds of host survival. The results of this study will eventually lead to the development of an improved therapeutic treatment for EBOV and help facilitate clinical trials in humans, a key step in the control and eradication of this highly infectious virus.
Program
Master's Award: Canada Graduate Scholarships
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311998
Name
de La Vega Marc-Antoine
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the mechanism of action of protective monoclonal antibodies against Ebolavirus
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immune Response; Animal Models; Antigenic Subversion; Ebolavirus; Innate; Level Iv Biocontainment; Monoclonal Antibodies; Sgp (Secreted Glycoprotein); Therapeutic Treatment; Viral Pathogenesis; Zmab
Abstract
Ebolavirus (EBOV) is one of the most aggressive pathogens known, and infections are characterized by a short incubation time as well as an onset of general symptoms, before rapidly progressing towards hemorrhage, shock and multi-system failure resulting in death in up to 90% of human cases. This virus has drawn considerable concern due to sporadic but devastating human outbreaks in sub-Saharan Africa, its suitability as a bio-weapon, and a prior instance of accidental introduction of EBOV to the USA from infected nonhuman primates (NHPs). Recent imported infections of the related Marburgvirus (MARV) to the Netherlands and the USA from tourists returning from travel in endemic areas have added to these concerns. The emergence of a new EBOV strain during the November 2007 outbreak in Uganda suggests that the virus is evolving. There are currently no prophylactic or therapeutic protocols approved for human use and current treatment consists only of palliative care. Previously, our research group has shown the importance of the humoral immune response in the context of host survival from EBOV infection. With this in mind, we developed a cocktail composed of three monoclonal antibodies (ZMAb) that when combined with adenovirus-vectored interferon as an adjuvant, is currently able to protect three of four cynomolgus macaques and four of four rhesus macaques when administered starting three days after EBOV infection. This is a significant achievement given that the current experimental options available have not been shown to be protective in NHPs if treatment is initiated past one hour after exposure to EBOV. Present research involves optimizing ZMAb, such that protection can still be achieved when administered later in the course of EBOV disease, or at lower antibody doses. However, the ability to further improve this treatment is hampered by the fact that the mechanism of action of these monoclonal antibodies is not yet known, although previous studies have indicated that antibody-mediated protection is not dependent on virus neutralization. The goal of this project is to elucidate this mechanism. EBOV sGP, a secreted form of the viral surface glycoprotein, is known to subvert the humoral response of the infected host such that potentially protective antibodies generated in response to the infection will cross-react with and be removed by sGP. We hypothesize that exogenous ZMAb acts by reducing sGP levels during infection and preventing the subversion of the humoral immune response, thereby improving the odds of host survival. The results of this study will eventually lead to the development of an improved therapeutic treatment for EBOV and help facilitate clinical trials in humans, a key step in the control and eradication of this highly infectious virus.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
de La Vega, Marc-Antoine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~